In conclusion, our data provide evidence that PARP3 drives TGFβ-mediated EMT and stem cell development in normal mammary and breast cancer cells and that these activities involve a PARP3 response to the generation of ROS. The gene discussed is PARP3; the disease is breast carcinoma.